DCRCC-RNA

DCRCC-RNA is an investigational autologous dendritic cell-based vaccine developed at Duke University for the treatment of renal cell carcinoma. The therapy is manufactured by isolating a patient's own dendritic cells and transfecting them with total messenger RNA (mRNA) extracted from the patient's own tumor cells. This approach allows the dendritic cells to express a broad spectrum of patient-specific tumor-associated antigens (TAAs). Once these mature, antigen-loaded cells are administered back to the patient, they migrate to the lymph nodes and present processed tumor epitopes to the immune system. This mechanism is designed to prime and activate a robust, polyvalent anti-tumor response involving both CD8+ cytotoxic T lymphocytes and CD4+ helper T cells. By targeting the full repertoire of expressed tumor antigens unique to the individual, the therapy aims to overcome tumor heterogeneity and minimize the risk of immune escape.

Other names

autologous tumor RNA-pulsed dendritic cell vaccineDC-RNA-RCC vaccineautologous tumor RNA-transfected dendritic cell vaccine